

WOODHEAD PUBLISHING SERIES IN BIOMEDICINE

# OCULAR TRANSPORTERS AND RECEPTORS

THEIR ROLE IN DRUG DELIVERY

EDITED BY ASHIM K. MITRA



**WP**  
WOODHEAD  
PUBLISHING

# Ocular transporters and receptors

## Woodhead Publishing Series in Biomedicine

- 1 **Practical leadership for biopharmaceutical executives**  
*J. Y. Chin*
- 2 **Outsourcing biopharma R&D to India**  
*P. R. Chowdhury*
- 3 **Matlab® in bioscience and biotechnology**  
*L. Burstein*
- 4 **Allergens and respiratory pollutants**  
*Edited by M. A. Williams*
- 5 **Concepts and techniques in genomics and proteomics**  
*N. Saraswathy and P. Ramalingam*
- 6 **An introduction to pharmaceutical sciences**  
*J. Roy*
- 7 **Patently innovative: How pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs**  
*R. A. Bouchard*
- 8 **Therapeutic protein drug products: Practical approaches to formulation in the laboratory, manufacturing and the clinic**  
*Edited by B. K. Meyer*
- 9 **A biotech manager's handbook: A practical guide**  
*Edited by M. O'Neill and M. H. Hopkins*
- 10 **Clinical research in Asia: Opportunities and challenges**  
*U. Sahoo*
- 11 **Therapeutic antibody engineering: Current and future advances driving the strongest growth area in the pharmaceutical industry**  
*W. R. Strobl and L. M. Strobl*
- 12 **Commercialising the stem cell sciences**  
*O. Harvey*
- 13 **Biobanks: Patents or open science?**  
*A. De Robbio*
- 14 **Human papillomavirus infections: From the laboratory to clinical practice**  
*F. Cobo*
- 15 **Annotating new genes: From *in silico* screening to experimental validation**  
*S. Uchida*
- 16 **Open-source software in life science research: Practical solutions in the pharmaceutical industry and beyond**  
*Edited by L. Harland and M. Forster*
- 17 **Nanoparticulate drug delivery: A perspective on the transition from laboratory to market**  
*V. Patravale, P. Dandekar and R. Jain*
- 18 **Bacterial cellular metabolic systems: Metabolic regulation of a cell system with <sup>13</sup>C-metabolic flux analysis**  
*K. Shimizu*

- 19 **Contract research and manufacturing services (CRAMS) in India: The business, legal, regulatory and tax environment**  
*M. Antani and G. Gokhale*
- 20 **Bioinformatics for biomedical science and clinical applications**  
*K-H. Liang*
- 21 **Deterministic versus stochastic modelling in biochemistry and systems biology**  
*P. Lecca, I. Laurenzi and F. Jordan*
- 22 **Protein folding *in silico*: Protein folding versus protein structure prediction**  
*I. Roterman*
- 23 **Computer-aided vaccine design**  
*T. J. Chuan and S. Ranganathan*
- 24 **An introduction to biotechnology**  
*W. T. Godbey*
- 25 **RNA interference: Therapeutic developments**  
*T. Novobrantseva, P. Ge and G. Hinkle*
- 26 **Patent litigation in the pharmaceutical and biotechnology industries**  
*G. Morgan*
- 27 **Clinical research in paediatric psychopharmacology: A practical guide**  
*P. Auby*
- 28 **The application of SPC in the pharmaceutical and biotechnology industries**  
*T. Cochrane*
- 29 **Ultrafiltration for bioprocessing**  
*H. Lutz*
- 30 **Therapeutic risk management of medicines**  
*A. K. Banerjee and S. Mayall*
- 31 **21st century quality management and good management practices: Value added compliance for the pharmaceutical and biotechnology industry**  
*S. Williams*
- 32 **Sterility, sterilisation and sterility assurance for pharmaceuticals**  
*T. Sandle*
- 33 **CAPA in the pharmaceutical and biotech industries: How to implement an effective nine step programme**  
*J. Rodriguez*
- 34 **TBC**
- 35 **Clinical trial management: An overview**  
*U. Sahoo and D. Sawant*
- 36 **Impact of regulation on drug development**  
*H. Guenter Hennings*
- 37 **Lean biomanufacturing**  
*N. J. Smart*
- 38 **Marine enzymes for biocatalysis**  
*Edited by A. Trincone*
- 39 **Ocular transporters and receptors in the eye: Their role in drug delivery**  
*A. K. Mitra*
- 40 **Stem cell bioprocessing: For cellular therapy, diagnostics and drug development**  
*T. G. Fernandes, M. M. Diogo and J. M. S. Cabral*
- 41 **Oral Delivery of Insulin**  
*T.A Sonia and Chandra P. Sharma*
- 42 **Fed-batch fermentation: A practical guide to scalable recombinant protein production in *Escherichia coli***  
*G. G. Moulton and T. Vedvick*

- 43 The funding of biopharmaceutical research and development  
*D. R. Williams*
- 44 Formulation tools for pharmaceutical development  
*Edited by J. E. Aguilar*
- 45 Drug-biomembrane interaction studies: The application of calorimetric techniques  
*Edited by R. Pignatello*
- 46 Orphan drugs: Understanding the rare drugs market  
*E. Hernberg-Ståhl*
- 47 Nanoparticle-based approaches to targeting drugs for severe diseases  
*J. L. Arias*
- 48 Successful biopharmaceutical operations: Driving change  
*C. Driscoll*
- 49 Electroporation-based therapies for cancer: From basics to clinical applications  
*Edited by R. Sundararajan*
- 50 Transporters in drug discovery and development: Detailed concepts and best practice  
*Y. Lai*
- 51 The life-cycle of pharmaceuticals in the environment  
*R. Braund and B. Peake*
- 52 Computer-aided applications in pharmaceutical technology  
*Edited by J. Djuris*
- 53 From plant genomics to plant biotechnology  
*Edited by P. Poltronieri, N. Burbulis and C. Fogher*
- 54 TBC
- 55 Quality assurance problem solving and training strategies for success in the pharmaceutical and life science industries  
*G. Welty*
- 56 Advancement in carrier based drug delivery  
*S. K. Jain and A. Jain*
- 57 Gene therapy: Potential applications of nanotechnology  
*S. Nimesh*
- 58 Controlled drug delivery: The role of self-assembling multi-task excipients  
*M. Mateescu*
- 59 *In silico* protein design  
*C. M. Frenz*
- 60 Bioinformatics for computer science: Foundations in modern biology  
*K. Revett*
- 61 Gene expression analysis in the RNA world  
*J. Q. Clement*
- 62 Computational methods for finding inferential bases in molecular genetics  
*Q-N. Tran*
- 63 NMR metabolomics in cancer research  
*M. Čuperlović-Culf*
- 64 Virtual worlds for medical education, training and care delivery  
*K. Kabol*

Woodhead Publishing Series in Biomedicine: Number 39

# Ocular transporters and receptors

*Their role in drug delivery*

EDITED BY  
ASHIM K. MITRA



Oxford   Cambridge   Philadelphia   New Delhi

Published by Woodhead Publishing Limited, 2013

Woodhead Publishing Limited, 80 High Street, Sawston, Cambridge, CB22 3HJ, UK  
www.woodheadpublishing.com  
www.woodheadpublishingonline.com

Woodhead Publishing, 1518 Walnut Street, Suite 1100, Philadelphia, PA 19102-3406, USA

Woodhead Publishing India Private Limited, G-2, Vardaan House, 7/28 Ansari Road,  
Daryaganj, New Delhi - 110002, India  
www.woodheadpublishingindia.com

First published in 2012 by Woodhead Publishing Limited  
ISBN: 978-1-907568-86-2 (print); ISBN 978-1-908818-31-7 (online)  
Woodhead Publishing Series in Biomedicine ISSN 2050-0289 (print); ISSN 2050-0297 (online)

© The editor, contributors and the Publishers, 2013

The right of Ashim K. Mitra to be identified as author(s) of the editorial material in this Work has been asserted by them in accordance with sections 77 and 78 of the Copyright, Designs and Patents Act 1988.

British Library Cataloguing-in-Publication Data: A catalogue record for this book is available from the British Library.

Library of Congress Control Number: 2013950746

All rights reserved. No part of this publication may be reproduced, stored in or introduced into a retrieval system, or transmitted, in any form, or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the Publishers. This publication may not be lent, resold, hired out or otherwise disposed of by way of trade in any form of binding or cover other than that in which it is published without the prior consent of the Publishers. Any person who does any unauthorised act in relation to this publication may be liable to criminal prosecution and civil claims for damages.

Permissions may be sought from the Publishers at the above address.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. The Publishers are not associated with any product or vendor mentioned in this publication.

The Publishers, editor(s) and contributors have attempted to trace the copyright holders of all material reproduced in this publication and apologise to any copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged, please write and let us know so we may rectify in any future reprint. Any screenshots in this publication are the copyright of the website owner(s), unless indicated otherwise.

#### **Limit of Liability/Disclaimer of Warranty**

The Publishers, editor(s) and contributors make no representations or warranties with respect to the accuracy or completeness of the contents of this publication and specifically disclaim all warranties, including without limitation warranties of fitness of a particular purpose. No warranty may be created or extended by sales of promotional materials. The advice and strategies contained herein may not be suitable for every situation. This publication is sold with the understanding that the Publishers are not rendering legal, accounting or other professional services. If professional assistance is required, the services of a competent professional person should be sought. No responsibility is assumed by the Publishers, editor(s) or contributors for any loss of profit or any other commercial damages, injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. The fact that an organisation or website is referred to in this publication as a citation and/or potential source of further information does not mean that the Publishers nor the editors(s) and contributors endorse the information the organisation or website may provide or recommendations it may make. Further, readers should be aware that internet websites listed in this work may have changed or disappeared between when this publication was written and when it is read. Because of rapid advances in medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Typeset by RefineCatch Limited, Bungay, Suffolk  
Printed in the UK and USA

---

# Contents

<i>List of figures and tables</i>	<i>xi</i>
<i>About the authors</i>	<i>xvii</i>
<b>1 Eye: anatomy, physiology and barriers to drug delivery</b>	<b>1</b>
<i>Kishore Cholkar, Supriya Reddy Dasari, Dhananjay Pal and Ashim K. Mitra</i>	
1.1 Introduction	2
1.2 Anatomy and physiology of the eye	2
1.3 Barriers to ocular drug delivery	18
1.4 Conclusions	27
1.5 Acknowledgements	28
1.6 References	28
<b>2 Biology of ocular transporters: efflux and influx transporters in the eye</b>	<b>37</b>
<i>Dhananjay Pal, Ramya Krishna Vadlapatla, Aswani Dutt Vadlapudi and Ashim K. Mitra</i>	
2.1 Introduction	38
2.2 SLC transporters	39
2.3 ABC transporters	55
2.4 Conclusions	67
2.5 References	68
<b>3 Characterization of ocular transporters</b>	<b>85</b>
<i>Animikh Ray, Kishore Cholkar, Zhiying Wang and Ashim K. Mitra</i>	
3.1 Introduction	85
3.2 Molecular and cellular characterization	86
3.3 Functional characterization of transporters	94
3.4 References	108



<b>4</b>	<b>Transporters and receptors in the anterior segment of the eye</b>	<b>115</b>
	<i>Kishore Cholkar, Animikh Ray, Vibhuti Agrahari, Dhananjay Pal and Ashim K. Mitra</i>	
4.1	Introduction	116
4.2	Transporters and receptors	118
4.3	Anterior chamber influx transporters	124
4.4	Anterior chamber efflux transporters	140
4.5	Anterior chamber receptors	142
4.6	Other miscellaneous anterior chamber receptors	152
4.7	Conclusions	156
4.8	References	156
<b>5</b>	<b>Transporters and receptors in the posterior segment of the eye</b>	<b>169</b>
	<i>Ashaben Patel, Mitan Gokulgandhi, Varun Khurana and Ashim K. Mitra</i>	
5.1	Introduction	170
5.2	Influx transporters in posterior segment of the eye	171
5.3	Receptors in posterior segment of the eye	188
5.4	ABC transporters	190
5.5	Conclusion	194
5.6	References	195
<b>6</b>	<b>Transporters in drug discovery and delivery: a new paradigm in ocular drug design</b>	<b>207</b>
	<i>Viral Tamboli, Sujay Shah and Ashim K. Mitra</i>	
6.1	Introduction	208
6.2	Transporter-targeted drug delivery to the anterior segment	209
6.3	Transporter-targeted drug delivery to the posterior segment	217
6.4	Conclusion	225
6.5	References	226
<b>7</b>	<b>Transporter–metabolism interplay in the eye</b>	<b>229</b>
	<i>Megha Barot, Mitesh Patel, Deep Kwatra and Ashim K. Mitra</i>	
7.1	Introduction	229
7.2	Metabolizing enzymes in ocular tissues	230
7.3	Impact of disease state on the expression of metabolizing enzymes	235

---

7.4	Efflux transporters and metabolism interplay	237
7.5	Potential impact of the efflux metabolism interplay in ocular bioavailability	239
7.6	Drug design and formulation strategies to overcome the efflux and metabolism interplay	241
7.7	Conclusion	242
7.8	References	243
	<b>Index</b>	<b>249</b>



---

## List of figures and tables

### Figures

1.1	Structure of human eye	3
1.2	Corneal layers of the eye	5
1.3	Diagram and electron micrograph images of the cornea, tear film–glycocalyx interface	6
1.4	Diagrammatic representation of anterior chamber of human eye with closed eye lids showing three distinct conjunctivas (bold layers)	7
1.5	Electron micrographs of the tear film surface of the conjunctiva epithelium	9
1.6	Flow direction of aqueous humor from iris to canal of Schlemm or towards cornea	10
1.7	Structure of human lens	11
1.8	Layers and histology of normal adult human retina	15
1.9	Diagrammatic representation of rod and cone cells of neural retina	17
1.10	Vernal conjunctivitis with conjunctival hypertrophy	21
1.11	Picture showing the pathway for tear drainage	23
1.12	Comparative relationships between <sup>14</sup> C-labeled permeants	25
1.13	Extracellular accumulation of debris in Bruch’s membrane (top) normal eye <i>vs</i> (bottom) diseased eye	26
2.1	Membrane topology of peptide transporter 1 (PEPT1)	41
2.2	Implications for proton-driven peptide symport	42
2.3	Proposed structure of MCT1 by homology modeling in the ‘closed’, the ‘open’ conformation with the inhibitor 4,4’-di-isothiocyanostilbene–2,2’-disulfonate (DIDS)	

bound and the 'open' conformation in association with the ancillary protein embigin	45
2.4 Primary structure and genomic organization of hATB <sup>(0,+)</sup>	48
2.5 (a) Model of the membrane topology of sodium-dependent multivitamin transporter (SMVT) protein deduced from the Kyte–Doolittle hydropathy plot (b) Predicted membrane topology of hSMVT and location of the conserved cysteine (Cys) residues	51
2.6 Schematic representation showing the two-dimensional structural model of the permeability glycoprotein P-gp	57
2.7 Models showing the transport mechanism of permeability glycoprotein, P-gp	59
2.8 Schematic representation showing the two-dimensional topological model of multidrug resistance-associated protein	61
2.9 Schematic showing the topology models of breast cancer resistance protein (BCRP) with the help of three different algorithms (A, B and C)	65
3.1 Diagrammatic representation of multichromogen immunohistochemical detection system that uses biotin-streptavidin and streptavidin enzyme links to react with chromogens	89
3.2 (a) Vitreal concentration–time profile of quinidine as control (0.75 µg alone) or in the presence of topically coadministered verapamil (100 µl, 0.5% weight/volume) at 2, 4 and 6 h after quinidine administration. (b) Vitreal concentration–time profile of quinidine as control (0.75 µg alone) or in the presence of topically coadministered verapamil (100 µl, 1.0% weight/volume) at 2, 4 and 6 h after quinidine administration	104
3.3 Dose–response relationship for the effect of homocysteine (Hcy) on the uptake of methyl tetrahydrofolate (MTF)	106
3.4 Kinetic analysis of methyl tetrahydrofolate (MTF) uptake in ARPE–19 cells treated with homocysteine (Hcy)	107
4.1 Transport routes across the blood–brain barrier	117
4.2 The concentration-dependent uptake of l-lactic acid in (a) primary human corneal epithelial cells (HCEpiC) and (b) human corneal epithelial (HCE) cells	131

4.3	Monocarboxylate transporter 1 (MCT1) and MCT4 protein expression in the human corneal epithelial cells.	132
4.4	Possible mechanism for ATP-binding cassette (ABC) protein-mediated transport	141
4.5	(a) Localization of insulin-like growth factor receptor $\beta$ (IGF-1R $\beta$ ) in corneal epithelial cells. (b) Juxtannuclear localization of IGF-1R $\beta$ .	144
4.6	Quantification by real time RT-PCR of endothelin $\alpha$ (ET $\alpha$ ) and ET $\beta$ expression in human iris (I), ciliary muscle (CM) and ciliary processes (CP)	154
5.1	Schematic picture of structure of retina and of transporters of outer and inner blood-retinal barriers.	171
5.2	The transmembrane topology of STRA6 is depicted in the upper picture. Physiological functions, likely evolutionary driving forces, and human diseases associated with these proteins are presented in the lower picture.	191
6.1	Transport of [ $^3$ H]Gly-Sar (0.5 $\mu$ Ci/mL), alone (control) or in the presence of ganciclovir (GCV) prodrugs (1 mM) across excised rabbit cornea	211
6.2	Transcorneal permeability of acyclovir (ACV), L-Asp-ACV and DAsp-ACV across isolated rabbit corneas, at 34 $^{\circ}$ C	213
6.3	Transcorneal permeability of L-Asp-acyclovir (ACV) alone (control) and in the presence of ouabain (1 mM) and glutamic acid (1 mM), B $^{0+}$ amino acid inhibitor (BCH) (5 mM) and sodium-free medium, across isolated rabbit corneas, at 34 $^{\circ}$ C, as a function of time	213
6.4	Cellular accumulation of [ $^{14}$ C]erythromycin (Ery, 0.25 $\mu$ Ci/mL) by rabbit primary corneal epithelial cells (rPCEC) in the presence of a specific permeability glycoprotein (P-gp) inhibitor (GF120918, 2 $\mu$ M), multidrug-resistance protein (MRP) inhibitor (MK571, 50 $\mu$ M), 6 $\alpha$ -methyl prednisolone (MPL, 500 $\mu$ M), prednisolone (PL, 500 $\mu$ M) and prednisone (PS, 500 $\mu$ M)	215
6.5	Aqueous humor concentration–time profile data of [ $^{14}$ C] erythromycin (10 $\mu$ Ci/mL) in the absence (filled diamond) and presence of 6 $\alpha$ -methyl prednisolone (X, MPL 500 $\mu$ M), prednisolone (unfilled triangle, PL 500 M) and prednisone (unfilled square, PS 500 $\mu$ M)	216

6.6	Anatomy of the eye showing the inner and outer blood–retinal barriers	217
6.7	Inhibition of [ <sup>3</sup> H]Gly-Sar uptake into the vitreous humor	218
6.8	Inhibition of [ <sup>3</sup> H]Gly-Sar uptake into the retina	219
6.9	Uptake of [ <sup>3</sup> H] biotin by ARPE–19 in the presence of pantothenic acid (10 μM and 200 μM), lipoic acid (10 μM and 200 μM), and desthiobiotin (10 μM and 200 μM)	221
6.10	Uptake of [ <sup>3</sup> H]biotin by ARPE–19 cells in the presence of Biotin-ganciclovir (GCV) at 200 μM, 1 mM and 2.5 mM concentrations	221
6.11	Retina–choroid (RC) and vitreal (V) ganciclovir (GCV) concentrations 4 h after administration to rabbits of GCV (control) or the prodrugs alone and in the presence of biotin	222
6.12	Response of ARPE–19 cells to enzyme-linked immunosorbent assay with rabbit anti-human monocarboxylate transporter 1 (MCT1) to MCT8 antibodies	224
7.1	Summary of interplay between efflux transporters and metabolizing enzymes	238
7.2	Summary of various drug transporters and metabolizing enzymes identified on ocular tissues	239
7.3	Illustration showing the vectoral nature of efflux metabolism interplay	240
7.4	Schematic for circumvention of efflux and metabolism by prodrug strategy	242

## Tables

2.1	Influx transporters and their localization in ocular tissues	53
2.2	Summary of some genomic properties and localization of multidrug-resistance-associated proteins (MRPs) 1–9	64
2.3	Mutational studies in breast cancer resistance protein (BCRP) predicting the role of important residues	66
2.4	Efflux transporters and their localization in ocular tissues	67